157 related articles for article (PubMed ID: 24757178)
1. Dynamic reprogramming of signaling upon met inhibition reveals a mechanism of drug resistance in gastric cancer.
Lai AZ; Cory S; Zhao H; Gigoux M; Monast A; Guiot MC; Huang S; Tofigh A; Thompson C; Naujokas M; Marcus VA; Bertos N; Sehat B; Perera RM; Bell ES; Page BD; Gunning PT; Ferri LE; Hallett M; Park M
Sci Signal; 2014 Apr; 7(322):ra38. PubMed ID: 24757178
[TBL] [Abstract][Full Text] [Related]
2. Sanguinarine inhibits growth and invasion of gastric cancer cells via regulation of the DUSP4/ERK pathway.
Zhang R; Wang G; Zhang PF; Zhang J; Huang YX; Lu YM; Da W; Sun Q; Zhu JS
J Cell Mol Med; 2017 Jun; 21(6):1117-1127. PubMed ID: 27957827
[TBL] [Abstract][Full Text] [Related]
3. KRC-408, a novel c-Met inhibitor, suppresses cell proliferation and angiogenesis of gastric cancer.
Hong SW; Jung KH; Park BH; Zheng HM; Lee HS; Choi MJ; Yun JI; Kang NS; Lee J; Hong SS
Cancer Lett; 2013 May; 332(1):74-82. PubMed ID: 23348694
[TBL] [Abstract][Full Text] [Related]
4. Testican-1-mediated epithelial-mesenchymal transition signaling confers acquired resistance to lapatinib in HER2-positive gastric cancer.
Kim HP; Han SW; Song SH; Jeong EG; Lee MY; Hwang D; Im SA; Bang YJ; Kim TY
Oncogene; 2014 Jun; 33(25):3334-41. PubMed ID: 23873022
[TBL] [Abstract][Full Text] [Related]
5. Resistance to small molecule inhibitors of epidermal growth factor receptor in malignant gliomas.
Li B; Chang CM; Yuan M; McKenna WG; Shu HK
Cancer Res; 2003 Nov; 63(21):7443-50. PubMed ID: 14612544
[TBL] [Abstract][Full Text] [Related]
6. DUSP4 Inactivation Leads to Reduced Extracellular Signal‒Regulated Kinase Activity through Upregulation of DUSP6 in Melanoma Cells.
Kamada H; Yasuhira S; Shibazaki M; Amano H; Maesawa C
J Invest Dermatol; 2022 Sep; 142(9):2499-2507.e6. PubMed ID: 35189148
[TBL] [Abstract][Full Text] [Related]
7. Oncogenic KRAS and BRAF activation of the MEK/ERK signaling pathway promotes expression of dual-specificity phosphatase 4 (DUSP4/MKP2) resulting in nuclear ERK1/2 inhibition.
Cagnol S; Rivard N
Oncogene; 2013 Jan; 32(5):564-76. PubMed ID: 22430215
[TBL] [Abstract][Full Text] [Related]
8. Gene methylation in gastric cancer.
Qu Y; Dang S; Hou P
Clin Chim Acta; 2013 Sep; 424():53-65. PubMed ID: 23669186
[TBL] [Abstract][Full Text] [Related]
9. Profiling of residual breast cancers after neoadjuvant chemotherapy identifies DUSP4 deficiency as a mechanism of drug resistance.
Balko JM; Cook RS; Vaught DB; Kuba MG; Miller TW; Bhola NE; Sanders ME; Granja-Ingram NM; Smith JJ; Meszoely IM; Salter J; Dowsett M; Stemke-Hale K; González-Angulo AM; Mills GB; Pinto JA; Gómez HL; Arteaga CL
Nat Med; 2012 Jul; 18(7):1052-9. PubMed ID: 22683778
[TBL] [Abstract][Full Text] [Related]
10. Overexpression of PI3K p110α contributes to acquired resistance to MET inhibitor, in MET-amplified SNU-5 gastric xenografts.
Ji F; Liu X; Wu Y; Fang X; Huang G
Drug Des Devel Ther; 2015; 9():5697-704. PubMed ID: 26543351
[TBL] [Abstract][Full Text] [Related]
11. Loss of BOP1 confers resistance to BRAF kinase inhibitors in melanoma by activating MAP kinase pathway.
Gupta R; Bugide S; Wang B; Green MR; Johnson DB; Wajapeyee N
Proc Natl Acad Sci U S A; 2019 Mar; 116(10):4583-4591. PubMed ID: 30782837
[TBL] [Abstract][Full Text] [Related]
12. Dual specificity phosphatase (DUSP)-4 is induced by platelet-derived growth factor -BB in an Erk1/2-, STAT3- and p53-dependent manner.
Yin R; Eger G; Sarri N; Rorsman C; Heldin CH; Lennartsson J
Biochem Biophys Res Commun; 2019 Nov; 519(3):469-474. PubMed ID: 31526568
[TBL] [Abstract][Full Text] [Related]
13. Expression of the MAP kinase phosphatase DUSP4 is associated with microsatellite instability in colorectal cancer (CRC) and causes increased cell proliferation.
Gröschl B; Bettstetter M; Giedl C; Woenckhaus M; Edmonston T; Hofstädter F; Dietmaier W
Int J Cancer; 2013 Apr; 132(7):1537-46. PubMed ID: 22965873
[TBL] [Abstract][Full Text] [Related]
14. Pharmacological inhibition of DUSP6 suppresses gastric cancer growth and metastasis and overcomes cisplatin resistance.
Wu QN; Liao YF; Lu YX; Wang Y; Lu JH; Zeng ZL; Huang QT; Sheng H; Yun JP; Xie D; Ju HQ; Xu RH
Cancer Lett; 2018 Jan; 412():243-255. PubMed ID: 29050982
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of Src impairs the growth of met-addicted gastric tumors.
Bertotti A; Bracco C; Girolami F; Torti D; Gastaldi S; Galimi F; Medico E; Elvin P; Comoglio PM; Trusolino L
Clin Cancer Res; 2010 Aug; 16(15):3933-43. PubMed ID: 20628031
[TBL] [Abstract][Full Text] [Related]
16. Statins affect ETS1-overexpressing triple-negative breast cancer cells by restoring DUSP4 deficiency.
Jung HH; Lee SH; Kim JY; Ahn JS; Park YH; Im YH
Sci Rep; 2016 Sep; 6():33035. PubMed ID: 27604655
[TBL] [Abstract][Full Text] [Related]
17. Role of RAF/MEK/ERK pathway, p-STAT-3 and Mcl-1 in sorafenib activity in human pancreatic cancer cell lines.
Ulivi P; Arienti C; Amadori D; Fabbri F; Carloni S; Tesei A; Vannini I; Silvestrini R; Zoli W
J Cell Physiol; 2009 Jul; 220(1):214-21. PubMed ID: 19288493
[TBL] [Abstract][Full Text] [Related]
18. Non-steroidal anti-inflammatory drugs suppress the ERK signaling pathway via block of Ras/c-Raf interaction and activation of MAP kinase phosphatases.
Pan MR; Chang HC; Hung WC
Cell Signal; 2008 Jun; 20(6):1134-41. PubMed ID: 18374541
[TBL] [Abstract][Full Text] [Related]
19. Critical role of extracellular signal-regulated kinase phosphorylation on menadione (vitamin K3) induced growth inhibition.
Osada S; Saji S; Osada K
Cancer; 2001 Mar; 91(6):1156-65. PubMed ID: 11267961
[TBL] [Abstract][Full Text] [Related]
20. KRAS mutant lung cancer cells are differentially responsive to MEK inhibitor due to AKT or STAT3 activation: implication for combinatorial approach.
Yoon YK; Kim HP; Han SW; Oh DY; Im SA; Bang YJ; Kim TY
Mol Carcinog; 2010 Apr; 49(4):353-62. PubMed ID: 20358631
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
